Roivant Sciences Stock
Roivant Sciences Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Matthew Gline
- Employees
- 721
- Market cap
- $24.2 B
- IPO
- 08/12/2020
- Web
- roivant.com
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company operating within the Healthcare sector and the Biotechnology industry. Headquartered in London, United Kingdom, the firm was founded in 2014 and currently employs 721 employees. The company's core business model focuses on discovering and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Roivant Sciences stock: price history
1D
-1.5%
1W
-5.4%
1M
-15.3%
6M
+12.4%
YTD
+54.5%
1Y
+96.0%
2Y
+180.1%
5Y
+457.0%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~14% stronger price swings than usual
Roivant Sciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Roivant Sciences Ltd. is a biopharmaceutical company specializing in the discovery and development of innovative therapeutic medications. The business model focuses on building a comprehensive pipeline for treating diverse diseases. Research priorities encompass oncological conditions such as solid tumors, hematological disorders such as sickle cell disease, and rare diseases such as hypophosphatasia. Additionally, the company addresses immunological and dermatological disorders as well as infectious diseases such as staphylococcal bacteremia. The company pursues a broad-based approach across various medical indications.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Roivant Sciences
Analyst assessment of Roivant Sciences
PRICE TARGET LOW
US$41.00
CONSENSUS
US$47.71
MEDIAN
US$47.00
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
14
BUY
2
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 12/10/2026
Roivant Sciences stock metrics
P/E
-88.24
P/B
5.71
EV/EBITDA
-80.4
RETURN ON EQUITY
-4.5%
NET MARGIN
-13,164.4%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.6%
FLOAT SHARES
581,939,537
AVG. DAILY VOLUME (30D)
7,675,313
Insider transactions (SEC)
Epperly Melissa B,
Epperly Melissa B,
Epperly Melissa B,
Venker Eric
Torti Frank
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.5%
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Roivant Sciences stock
What does Roivant Sciences do?
Roivant Sciences Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Matthew Gline, the company employs around 721 people.
The IPO was on 08/12/2020; the stock trades on NASDAQ under the ticker ROIV.
What do analysts say about Roivant Sciences stock?
16 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$47.71, ranging from US$41.00 to US$55.00, with a median of US$47.00.
This is an external assessment, not a statement by Market Jury.
When does Roivant Sciences report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 14% stronger than usual.
Does Roivant Sciences pay a dividend?
No, Roivant Sciences currently does not pay a dividend.
Which stocks are comparable to Roivant Sciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Roivant Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Roivant Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.